| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(17)30168-7 |
| P8608 | Fatcat ID | release_l7ir45nntfhj5g2ednvjekfedq |
| P698 | PubMed publication ID | 28283282 |
| P50 | author | Fred Saad | Q88065306 |
| Celestia Higano | Q126877419 | ||
| P2093 | author name string | Martin Gleave | |
| Arnulf Stenzl | |||
| Johann S de Bono | |||
| Axel S Merseburger | |||
| Kim N Chi | |||
| Jean-Marc Ferrero | |||
| Andries M Bergman | |||
| Som D Mukherjee | |||
| Susan Feyerabend | |||
| Pawel Zalewski | |||
| Gwenaelle Gravis | |||
| Brent Blumenstein | |||
| James Reeves | |||
| Cindy Jacobs | |||
| P2860 | cites work | Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. | Q36058291 |
| Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report | Q38446418 | ||
| Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy | Q38458031 | ||
| Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. | Q38892734 | ||
| Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. | Q39172440 | ||
| Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. | Q39262037 | ||
| Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy | Q40003248 | ||
| Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Q41082307 | ||
| Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. | Q42927772 | ||
| Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. | Q42928474 | ||
| Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. | Q43661967 | ||
| Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. | Q44187537 | ||
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 | Q45957143 | ||
| A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer | Q46689589 | ||
| Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins | Q57639622 | ||
| Clusterin expression and univariate analysis of overall survival in human breast cancer | Q79377021 | ||
| Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma | Q82264106 | ||
| Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer | Q83831101 | ||
| Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer | Q86563090 | ||
| Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state | Q24290651 | ||
| Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells | Q24294824 | ||
| Clusterin inhibits apoptosis by interacting with activated Bax | Q24316499 | ||
| Targeting the adaptive molecular landscape of castration-resistant prostate cancer | Q27022821 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial | Q28294857 | ||
| The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival | Q30611108 | ||
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group | Q33566395 | ||
| Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 | ||
| Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin | Q34780639 | ||
| Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial | Q35572535 | ||
| P433 | issue | 4 | |
| P921 | main subject | docetaxel | Q420436 |
| multicenter clinical trial | Q6934595 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 473-485 | |
| P577 | publication date | 2017-03-07 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. | |
| P478 | volume | 18 |
| Q95261850 | A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy |
| Q52373640 | A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). |
| Q88912942 | Alternative splicing and cancer metastasis: prognostic and therapeutic applications |
| Q64247127 | Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis |
| Q57107233 | Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer? |
| Q90590631 | Cellular rewiring in lethal prostate cancer: the architect of drug resistance |
| Q48282746 | Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. |
| Q64087689 | Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies |
| Q94528678 | Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel |
| Q47651210 | Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, internation |
| Q50850244 | Drug development in prostate cancer: time to embrace RECIST? |
| Q48288989 | Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. |
| Q57286596 | Glucocorticoids Induce Stress Oncoproteins Associated with Therapy-Resistance in African American and European American Prostate Cancer Cells |
| Q90194623 | Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities |
| Q90293688 | Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials |
| Q64257298 | Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer |
| Q46462659 | Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer |
| Q90699186 | Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel |
| Q92451337 | Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer |
| Q87690991 | Prostate cancer: Custirsen fails to improve outcomes |
| Q92025247 | Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment |
| Q92702584 | The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer |
| Q64110791 | The role of Clusterin in cancer metastasis |
| Q95923721 | Tumour Cell Secretome in Chemoresistance and Tumour Recurrence |
| Q48762558 | Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse". |
| Q38745926 | Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. |
Search more.